Determining If You Need Psychiatric Medication
According to the demographics in research, anyone can develop a mental illness. Although some disorders are mild, others are serious and long-lasting.
Fortunately, many of these conditions can be helped with a variety of interventions.
The primary treatment methods for psychiatric disorders are psychotherapy, psychotherapeutic medications, and other complementary and alternative therapies.
One of the biggest challenges that someone can face is whether to take medications.
There are four large categories of psychotherapeutic medications based on the symptoms for which they are primarily used:
antipsychotic, antimanic, antidepressant, and antianxiety medications. In addition, stimulants are used for attention deficit/hyperactivity disorder.
Compared to other types of treatment, psychotherapeutic medications are relative newcomers in the fight against mental illness.
This is even true as compared to complementary and alternative treatments as many of them have been around for thousands of years.
The first psychotherapeutic medication, chlorpromazine, was introduced 41 years ago. These medications have made substantial changes in the
treatment of mental disorders. People who previously would have spent years in mental hospitals may now only go in for brief treatment,
or might receive treatment at an outpatient clinic.
In some instances, psychotherapeutic medications can make other kinds of treatment more effective. For example, someone who is too
psychotic to talk, for instance, cannot get any benefit from psychotherapy. In these types of situations, the appropriate medication
may improve symptoms enough so that the person can participate in therapy.
Symptom Relief, Not A Cure
One of the problems with psychotherapeutic medications is that they tend to mask the problem by only reducing the symptoms. In othert words, they
don't actually get rid of the problem. These is even true of other the counter medications. For example, aspirin can reduce a fever without
clearing up an infection that is causing it. Similarly, psychotherapeutic medications act by controlling symptoms. Like most drugs used in
medicine, they correct or compensate for a biological malfunction and do not actually cure the illness.
Although psychotherapeutic medications do not cure mental illness, but can lessen discomfort and behaviors.
In many cases, these medications can help a person get on with life despite side effects, continuing mental pain, and difficulty coping.
For example, antipsychotic drugs like chlorpromazine can eliminate auditory hallucinations experiences in schizophrenia.
The length of time someone must take a psychotherapeutic medication depends on the disorder. Many people schizophrenia may have to be
take indefinitely. Other people with less severe problems, such as mild anxiety, may need medication for a single period perhaps for several months
and then never have to take it again.
Problems with Reliability and Effectiveness
Like many substances, psychotherapeutic medications do not produce the same effect in everyone. Some people may respond better to one
medication than another while others may need larger dosages than others. One person might experience annoying even life-threatening
side effects while another does not. Everything affects a person's reaction to a particular drug, including age, sex, body size, genetics,
and diet.
Recently, the effectiveness of the most popular group pf psychotherapeutic medications has come into serious question. A large number of studies have shown that antidepressant medications do not work any better than sugar pills for depression, even the severest forms. This is not to say that antidepressants don't work; the studies showed that while antidepressants do work to reduce the symptoms of depression, sugar pills work just as well, and without the side effects.
Questions for Your Psychiatrist
If you're experiencing mental illness and thinking about taking medication, it's important to see a psychiatrist as opposed to a general doctor. This is because a psychiatrist receives exponentially more education and experience with psychotherapeutic medication than does a general physician. To increase the likelihood that a medication will work well, a patient needs to actively participate with the psychiatrist, such as explaining past medical history, and other substances being taken, including medications, supplements, and herbal preparations.
According to the he U.S. Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH), a patient should ask a doctor
the following questions before taking any medication:
What is the name of the medication, and what is it supposed to do?
How and when do I take it, and when do I stop taking it?
What foods, drinks, other medications, or activities should I avoid while taking the prescribed medication?
What are the side effects, and what should I do if they occur?
Is there any written information available about the medication?
Although many treatment evaluation studies have examined the efficacy of the psychotherapeutic medications, much remains to be learned about
these medications. The National Institute of Mental Health, other Federal agencies, and private research groups are sponsoring studies of
these medications on an ongoing basis. Scientists hope to improve their understanding of how and why these medications work, how to
control or eliminate unwanted and dangerous side effects, and how to make the medications more effective. Meanwhile, complementary and alternative
medicine has become the first choice of many people suffering from mental illness who do not want to experience the
side effects of psychotherapeutic medication.
References (To view, roll mouse over the "References" heading; to hide, click on the heading)
American Psychiatric Association (2000), Diagnostic and statistical manual of mental
disorders. (4th Ed.). Washington, DC: American Psychiatric Association.
Anderson, G. M., Segman, R. H. & King, R. A. (1995). Serotonin and suicidality: the impact of fluoxetine administration. II: Acute neurobiological effects.
Israel Journal of Psychiatry and Related Sciences, 32(1), 44-50.
Barcley, L. (2007). Fighting depression and improving cognition with omega-3 fatty acids. Life Extension, October, 65-71.
Barnes, P. M., Bloom, B., & Nahin, R. L. (2009). Complementary and alternative medicine use among adults and children: United States, 2007. National Health Statistics Reports, 12, 1-23.
Barnes, P. M., Powell-Griner, E., McFann, K., & Nahin, R. L. (2004). Complementary and alternative medicine use among adults: United States, 2002. National Center for Health Statistics, 2004. Advance Data, 343, 1-19.
Cohen, J. (2001). Over dose: The case against the drug companies: Prescription drugs, side effects, and your health. New York: Jeremy P. Tarcher.
Donovan, S., Clayton, A., et al. (2000). Deliberate self-harm and antidepressant drugs. Investigation of a possible link. British Journal of Psychiatry, 177, 551-556.
Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Van Rompay, M., & Kessler, R. C. (1998). Trends in alternative medicine
use in the United States, 1990-1997: Results of a follow-up national survey. Journal of the American Medical Association, 280(18), 1569-1575.
Eisenberg, D. M., Kessler, R. C., Foster, C., Norlock, F. E., Calkins, D. R., & Delbanco, T. L. (1993). Unconventional medicine in the United States: Prevalence, costs, and patterns of use. New England Journal Medicine, 328, 246-252.
Fredricks, R. (2008). Healing & wholeness: Complementary and alternative therapies for mental health. Bloomington, IN: Author House.
Fournier, J. C., DeRubeis, R. J. , Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C.,& Fawcett, J. (2010).
Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA,303(1),47-53.
Goodwin, F. K., & Jamison, K. R. (19990). Manic-depressive illness. Oxford University Press: New York.
Guze, S. B, & Robins, E. (1970). Suicide and affective disorders. British Journal Psychiatry, 117, 437-438.
Holzman, D. (2009). Tamoxifen, antidepressants, and CYP2D6: The conundrum continues. J Natl Cancer Inst, 101(20), 1370-1371.
Khan, A., Leventhal, R. M., Khan, S., & Brown, W. A. (2002). Severity of depression and response to antidepressants and placebo: An analysis
of the Food and Drug Administration database. Journal of Clinical Psychopharmacology, 22, 40-45.
Kirsch, I. (2008). Challenging received wisdom: Antidepressants and the placebo effect. Mcgill Journal of Medicine, 11(2), 219-222.
Lasser, K. E., Alan, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287, 2215-2220.
Medical Economics. (1994). Physicians' desk reference. Montvale, NJ: Medical Economics Data Production Company.
Medco Health Solutions. (2009). Popular breast cancer drug used with certain antidepressants puts New Jersey women at risk. Retrieved
January 6, 2010 from http://www.medcohealth.com/medco/corporate/home.jsp?ltSess=y&articleID=CorpAlertMedco_tamoxifen_risk
Moshiri, E., Basti, A. A., Noorbala, A. A., Jamshidi, A. H., Hesameddin Abbasi, S., & Akhondzadeh, S. (2006). Crocus sativus L. (petal) in the treatment
of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine, 13, 607-611.
National Institute of Mental Health. (1992). New developments in pharmacologic treatment of schizophrenia. Rockville, MD: National Institute of Mental Health.
Rispail, Y., Schmitt, L., Berlan, M., Montastruc, J. L., & Montastruc, P. (1990). Yohimbine increases salivary secretion in depressed patients
treated with tricyclic antidepressants. European Journal of Clinical Pharmacology, 39(4), 425-426.
Rosack, J. (2005). Suicide rates began to drop with advent of SSRIs. Psychiatric News, 40(7), 29.
Rosack, J. (2006). MAOI skin patch wins DFA approval for depression. Psychiatric News, 41(7), 31.
Rorsman, B., Gräsbeck, A., Hagnell, O., Lanke, J., Öhman, R., Öjesjö, L., & Otterbeck, L. A. (1990). Prospective study of first-incidence depression: The Lundby Study, 1957-72. British Journal of Psychiatry, 156, 336-342.
Shergill, S. S., & Katona, C. L. (1997). Pharmacological choices after one antidepressant fails: A survey of UK psychiatrists. Journal of Affective Disorders, 43, 19-25.
Smoller, J. W., Allison, M., Cochrane, B. B., Curb, J. D., Perlis, R. H., Robinson, J. G., Rosal, M. C,, Wenger, N. K., & Wassertheil-Smoller, S. (2009).
Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women In the women's health initiative study.
Arch Intern Med, 169(22), 2128-2139.
Waechter, F. (2003). Paroxetine must not be given to patients under 18. BMJ, 326, 1282.